Abstract
Background: Central nervous system disorders such as anxiety, depression and epilepsy are characterized by sharing several molecular mechanisms in common and the involvement of the L-arginine/NO pathway in neurobehavioral studies with β-caryophyllene is still little discussed.
Objectives: One of the objectives of the present study was to demonstrate the anxiolytic behavioral effect of β-caryophyllene (β-CBP) in female Swiss mice, as well as to investigate the molecular mechanisms underlying the results obtained.
Methods: This study evaluated the neurobehavioral effects of β-CBP using the open field test, rota- rod test, elevated plus maze test, novelty suppressed feeding test, tail suspension test and forced swim test, as well as pilocarpine, pentylenetetrazole and isoniazid-induced epileptic seizure models.
Results: The results demonstrated that the neuropharmacological activities of β-CBP may involve benzodiazepine/GABAergic receptors, since the pre-treatment of β-CBP (200 mg/kg) associated with flumazenil (5 mg/kg, benzodiazepine receptor antagonist) and bicuculline (1 mg/kg, selective GABAA receptor antagonist) reestablished the anxiety parameters in the elevated plus-maze test, as well as the results of reduced latency to consume food in the novelty suppressed feeding test. In addition to benzodiazepine/GABAergic receptors, the neuropharmacological properties of β-CBP may be related to inhibition of nitric oxide synthesis, since pre-treatment with L-arginine (500-750 mg/kg) reversed significantly the anxiolytic, antidepressant and anticonvulsant activities of β-CBP.
Conclusion: The results obtained provide additional support in understanding the neuromolecular mechanisms underlying the anxiolytic, antidepressant and anticonvulsive properties of β-CBP in female Swiss mice.
Keywords: β-caryophyllene, benzodiazepine/GABAergic receptors, neurobehavioral effects, neuromolecular mechanisms, nitric oxide, L-arginine/NO pathway.
Graphical Abstract
[http://dx.doi.org/10.1073/pnas.0803601105] [PMID: 18574142]
[http://dx.doi.org/10.1007/978-3-642-22144-6_183]
[http://dx.doi.org/10.1021/ie301294f]
[http://dx.doi.org/10.1016/j.indcrop.2012.09.010]
[http://dx.doi.org/10.1016/j.yrtph.2017.12.013] [PMID: 29258925]
[http://dx.doi.org/10.1016/j.neuropharm.2017.07.015] [PMID: 28729222]
[http://dx.doi.org/10.1016/j.pbb.2014.06.025] [PMID: 24999220]
[http://dx.doi.org/10.1002/mnfr.201600197] [PMID: 27234712]
[PMID: 27913825]
[http://dx.doi.org/10.1016/j.biopha.2017.04.092] [PMID: 28463791]
[http://dx.doi.org/10.1016/j.cbi.2015.12.019] [PMID: 26748309]
[http://dx.doi.org/10.1016/j.intimp.2017.07.009] [PMID: 28821008]
[http://dx.doi.org/10.1016/j.physbeh.2014.06.003] [PMID: 24930711]
[http://dx.doi.org/10.1016/j.bbr.2019.112439] [PMID: 31862467]
[http://dx.doi.org/10.1016/j.neuroscience.2014.08.043] [PMID: 25194788]
[http://dx.doi.org/10.1016/j.yebeh.2015.12.040] [PMID: 26827298]
[http://dx.doi.org/10.1159/000362689] [PMID: 25171128]
[http://dx.doi.org/10.1007/s11010-016-2733-y] [PMID: 27316720]
[http://dx.doi.org/10.1016/j.gene.2017.04.048] [PMID: 28465168]
[http://dx.doi.org/10.1038/npp.2014.137] [PMID: 24917196]
[http://dx.doi.org/10.1016/j.neuropharm.2011.08.040] [PMID: 21889518]
[http://dx.doi.org/10.1016/j.lfs.2018.08.050] [PMID: 30144453]
[http://dx.doi.org/10.1016/j.cbi.2015.10.003] [PMID: 26456888]
[http://dx.doi.org/10.1038/nprot.2006.20] [PMID: 17406223]
[PMID: 2162942]
[http://dx.doi.org/10.1126/science.1083328] [PMID: 12907793]
[http://dx.doi.org/10.1016/0278-5846(87)90002-9] [PMID: 2894041]
[http://dx.doi.org/10.1016/0014-2999(78)90118-8] [PMID: 204499]
[http://dx.doi.org/10.1016/j.physbeh.2004.01.013] [PMID: 15135013]
[http://dx.doi.org/10.1016/j.pnpbp.2012.04.012] [PMID: 22542869]
[http://dx.doi.org/10.1016/0031-9384(94)90090-6] [PMID: 8022922]
[http://dx.doi.org/10.1016/0166-4328(94)90008-6] [PMID: 7913324]
[http://dx.doi.org/10.1016/0091-3057(88)90413-3] [PMID: 3252289]
[http://dx.doi.org/10.1007/s11064-014-1474-0] [PMID: 25417010]
[http://dx.doi.org/10.1038/s41598-017-15628-7] [PMID: 29138471]
[http://dx.doi.org/10.1177/2398212819858249] [PMID: 32166183]
[http://dx.doi.org/10.1016/j.neuropharm.2018.01.036] [PMID: 29407219]
[http://dx.doi.org/10.1002/mnfr.201300420] [PMID: 24273211]
[http://dx.doi.org/10.1016/j.ajpath.2010.11.052] [PMID: 21356367]
[http://dx.doi.org/10.1016/j.neulet.2014.12.003] [PMID: 25481767]
[http://dx.doi.org/10.3389/fnins.2016.00321] [PMID: 27531971]
[http://dx.doi.org/10.1073/pnas.1413210111] [PMID: 25368177]
[http://dx.doi.org/10.1016/S0014-2999(02)02331-2] [PMID: 12359270]
[http://dx.doi.org/10.1124/jpet.103.051920] [PMID: 12954810]
[http://dx.doi.org/10.1016/B978-0-12-809825-7.00002-X]
[http://dx.doi.org/10.2174/1871527317666180420150249] [PMID: 29676236]
[http://dx.doi.org/10.1016/j.ejphar.2011.11.009] [PMID: 22115892]
[http://dx.doi.org/10.1089/jmf.2012.2283] [PMID: 23734999]
[http://dx.doi.org/10.1016/j.yebeh.2017.08.039] [PMID: 28931473]
[http://dx.doi.org/10.1016/j.pharmthera.2019.107402] [PMID: 31470029]
[http://dx.doi.org/10.2174/1381612822666160311115226] [PMID: 26965491]
[http://dx.doi.org/10.1177/1091581816655303] [PMID: 27358239]
[http://dx.doi.org/10.1016/j.fct.2019.110876] [PMID: 31610257]
[http://dx.doi.org/10.1111/jnc.13833] [PMID: 27565895]